WHAT: A group of private donors has gifted funds to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, making it what’s believed to be the first such research center in the U.S., and the largest research center of its kind in the world.
Psychedelics are a class of drugs that produce unique and profound changes of consciousness over the course of several hours. Much of the early work at Johns Hopkins has focused on psilocybin, the chemical found in so-called magic mushrooms.A teleconference will announce more details on the center, including its goals and makeup, and the people essential to establishing the center. The teleconference will also provide a peek into new research projects that hopefully will improve human health and wellness.
WHEN:Wednesday, Sept. 4, 12 p.m. EDT
WATCH:A live webcast can be viewed here on the Johns Hopkins Periscope channel. Reporters can ask questions live on Periscope.
CALL IN:Members of the press can participate via telephone — dial 800-230-1092 from the United States, international callers can dial 612-288-0329. The conference ID number for U.S. and international callers is 471252. A moderator will manage reporter questions.
- Roland Griffiths, Ph.D., the center’s director and professor of behavioral biology in the Department of Psychiatry and Behavioral Sciences and the Department of Neuroscience at the Johns Hopkins University School of Medicine
- Matthew Johnson, Ph.D., the center’s assistant director and associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine
- Tim Ferriss, philanthropist, author and technology investor
Reporters may submit questions to be read and answered during the press conference by sending an email to JHMedia@jhmi.edu. (Questions can also be sent after the event.) Please include your first and last name and your media outlet. Use PSYCHEDELIC CENTER in the subject line.
FOR MORE INFORMATION:
Highlights and live updates from the event will be posted on Twitter via @HopkinsMedNews.